BZW1 Promotes Cell Proliferation in Prostate Cancer by Regulating TGF-β1/Smad Pathway

Teng-Cheng Li
sun yat-sen university

Zhuo-Lun Sun
Sun Yat-Sen University

Chu-Tian Xiao
Sun Yat-Sen University

Jie-Ying Wu
Sun Yat-Sen University

Ke Li (li202031@163.com)
Sun Yat-Sen University

Research article

Keywords: BZW1, prognosis, Prostate cancer, survival, biomarker

DOI: https://doi.org/10.21203/rs.3.rs-45376/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background Recently, basic leucine zipper and the W2 domain-containing protein 1 (BZW1) is reported to be implicated in tumor progression. However, the role of BZW1 in prostate cancer remains unknown. This study is aimed to investigate the expression of BZW1 and its influence on cell proliferation in prostate cancer.

Methods The expression levels of BZW1 were measured in 136 cases of prostate cancer and matched adjacent non-cancerous prostate tissues by quantificational real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). Then, the effect of BZW1 on cell proliferation was further explored.

Results QRT-PCR analysis shown that the mRNA levels of BZW1 in prostate cancer were significantly greater compared with those in matched adjacent non-cancerous prostate tissues ($P<0.001$). IHC results shown the high-expression rate of BZW1 in prostate cancer and matched adjacent non-cancerous prostate tissues were 68.4% and 32.4%, and the difference was statistically significant ($P<0.001$). BZW1 high-expression significantly correlated with T stage, lymph node metastasis, prostate specific antigen (PSA) and Gleason score ($P<0.05$). Patients with BZW1 high-expression presented unfavorable prognosis compared with those with BZW1 low-expression ($P=0.002$). In addition, CCK-8 and Colony formation assays revealed that BZW1 over-expression significantly promoted cell proliferation in vitro. Tumor xenograft shown BZW1 knockdown significantly inhibited tumor growth in vivo. Moreover, BZW1 overexpression activated the TGF-β1/Smad1/Smad3 pathway.

Conclusion BZW1 over-expression predicts poorer prognosis and promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway.

Background

Prostate cancer (PCa) is one of the most prevalent urological cancers in men worldwide [1–3]. The incidence of PCa is increased worldwide in recent years [4–5]. In the USA and Europe, PCa accounts for the second most leading cause of cancer-related mortality [6–7]. Although the testing of PSA was generally used in the early diagnosis, the incidence and mortality rate of PCa are still increasing [8–10]. Therefore, identifying new potential markers of prostate cancer is crucial for the early diagnosis and clinical therapy.

BZW1 is a member of the bZIP superfamily of transcription factors, which contains C-terminal W2-type HEAT domains [11–12]. BZW1 plays a key role in the cell cycle by regulating histone H4 gene transcription [13]. Moreover, BZW1 promotes cell proliferation in salivary mucoepidermoid carcinoma and lung adenocarcinoma [14–16]. BZW1 overexpression is an independent prognostic marker in lung adenocarcinoma [16]. However, the biological function of BZW1 in prostate cancer remains unknown.
Here, the expression of BZW1 and its clinical significance in prostate cancer were investigated. Moreover, the effect of BZW1 expression on cell proliferation and its potential mechanism were explored.

**Methods**

**Patients and samples**

A total of 136 prostate cancer and matched adjacent non-cancerous prostate tissues were enrolled in this study. All patients received surgery resection during 2010 to 2018, while no patient treated with chemotherapy or radiotherapy before surgery. Clinical pathological characters were obtained from hospitalized records. The follow-up time was ranged from 8 to 64 months. This study was supported by the ethics committee of Sun Yat-sen University (No. Z81771573) and performed in accordance with the Declaration of Helsinki. The informed consent was signed by each patient.

**Cell Culture And Transfection**

Human prostate cancer cell lines (PC3, Du145 and LnCap) were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cells were cultured with RPMI-1640 (Gibco) with 10% heat-inactivated fetal bovine serum (FBS, Hyclone) at 37 °C in a humidified incubator with 5% CO$_2$. Cell transfection was performed by Lipofectamine™ 2000 (Invitrogen, Thermo Fisher Scientific, Inc, USA) according to the manufacturer's instructions. Then, cells were cultured with 10% heat-inactivated fetal bovine serum (FBS, Hyclone) supplemented with puromycin (0.5 µg/mL). BZW1 down-regulation was performed by transferring shRNA lentivirus vectors (Genepharma, Suzhou, China) and BZW1 over-expression was performed by transferring recombinant lentivirus vectors (Genepharma, Suzhou, China). Non-target shRNA (Genepharma, Suzhou, China) lentivirus vectors were used as the negative control (NC).

**QRT-PCR**

Total RNA was extracted from fresh tissues and cells by using TRIzol Reagent (Life Technologies). According to the manufacturer's protocol, the RNA was reversed into cDNA using a PrimeScript RT kit (Takara, Dalian, China). Real-time quantitative PCR was performed by SYBR1 Premix Ex Taq (DDR041A, TaKaRa, Dalian, China). Primers for BZW1 were 5’-ACTGGTGTCTTCTGGCTAA-3’ (Forward) and 5’-GTGCTCATTACACTTGACCA-3’ (Reverse). The primer sequence for GAPDH were 5’-CTGAACGGGAAGCTCACTGG-3’ (Forward) and 5’-TGAGGTCCACCACCCTGTTG-3’ (Reverse). GAPDH was considered as the internal control and each test was repeated three times. The relative expression level of target genes was calculated using the $2^{-\Delta\Delta Ct}$ method.

**Western Blotting**
Proteins were extracted by radioimmunoprecipitation assay (RIPA) Lysis buffer (Abcam, Cambridge, MA, USA) and quantified by bicinchoninic acid (BCA) Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). 40 µg of protein per sample was separated onto 10% SDS-PAGE gels and transferred onto polyvinyl difluoride (PVDF) filter membrane (Bio-Rad, Hercules, CA, USA). Then, PVDF membranes were blocked with 5% non-fat dried milk for 2 h, and incubated with anti-BZW1 (1:1000, ABcam Corp, USA), anti-Smad1 (1:1000, ABcam Corp, USA), anti-p-Smad1 (1:1000, ABcam Corp, USA), anti-Smad3 (1:1000, ABcam Corp, USA), anti-p-Smad3 (1:1000, ABcam Corp, USA), anti-TGF-β1 (1:2000, ABcam Corp, USA) and anti-GAPDH (1:2000, ABcam Corp, USA), respectively at 4 °C overnight. Finally, membranes were incubated with secondary antibodies (horseradish peroxidase-conjugated anti-rabbit). Signals were developed using an enhanced chemiluminescence reaction kit (Applygen Technologies, Beijing, China).

**Immunohistochemistry (ihc)**

Tissue sections (Two-micrometre-thick) were deparaffinized with xylene and alcohol. Antigen retrieval was completed by sodium citrate buffer (pH 6.0). Then, sections were incubated with rabbit polyclonal BZW1 antibody (Abcam Corp, USA) (diluted 1:100) overnight at 4 °C. Sections were washed with Phosphate-Buffered Saline (PBS) and incubated with biotin-labeled secondary antibodies for 30 minutes at room temperature. Signals were detected by dianibenzidine tetrahydrochloride (DAB). PBS substituted with primary antibody was regarded as negative controls. The positive controls were performed by lung adenocarcinoma with positive expression of BZW1 [15]. The scores were calculated by the number of positive cells and staining intensity. Percentage of cells was recorded as 1 (< 25%), 2 (25%-50%) and 3 (> 51%). Staining intensity was recorded as blank (0), weak (1, +), moderate (2, ++) and strong (3, +++). Total score of each section was ranged from 0 to 9. Based on the semiquantitative analysis, BZW1 expression was scored as low-expression (< 4) and high-expression (≥ 4) [15].

**Cell counting kit-8 (CCK-8) analysis**

CCK-8 assay was used to evaluate the cell proliferation. Cells were transferred and seeded in 96-well plates (1.0 × 10^3 cell/well) for 5 days. Then, cells were cultured with 10 µL of CCK-8 (Dojindo, Kumamoto, Japan) for 3 h, and the optical density of each well was examined by a microplate reader (BioTek, Winooski, VT, USA) at 450 nm. Each test was repeated in triplicate at the same condition.

**Colony formation analysis**

Tansfected cells (1.0 × 10^3 cell/well) were seeded into 6-well plates. After 2 weeks, cells were obtained and fixed with 100% methanol. Then, cells were incubated with 0.1% crystal violet and stained with hemocytometer for counting. Each experiment was repeated in triplicate at the same condition.

**Tumor Xenograft In Vivo**
Balb/c nude mice (4 weeks old) were purchased from Animal Center and kept on specific pathogen-free conditions in accordance with institutional guidelines. To evaluate the effect of BZW1 on tumor growth, $6 \times 10^6$ prostate cancer cells with shRNA lentivirus vectors were subcutaneously injected into the flank regions of legs (5 mice per group). Negative controls (NC) were treated with prostate cancer cells with non-target shRNA lentivirus vectors. After 2 weeks, tumor size and tumor weight were calculated.

**Statistical analysis**

All data was characterized as mean ± standard deviation, and analyzed by SPSS software (version 19.0; SPSS, Chicago, IL, USA). The mRNA expression levels of BZW1 between prostate cancer and matched adjacent non-cancerous tissues were analyzed by paired $t$-test. The correlation between BZW1 expression and clinicalpathological characters was evaluated by Chi-square test ($\chi^2$). Survival analysis was performed by using the Kaplan-Meier method with log-rank test. Hazard Ratio (HR) was evaluated using the Cox’s proportional hazards model. $P<0.05$ was considered as statistical significance.

**Results**

**BZW1 is highly expressed in prostate cancer and correlated with clinicalpathological characters**

To evaluate the expression of BZW1, the mRNA levels of BZW1 were detected in 136 cases of prostate cancer and matched adjacent non-cancerous prostate tissues by qRT-PCR. Results shown the mRNA levels of BZW1 was significantly greater in prostate cancer compared with those in matched adjacent non-cancerous prostate tissues (Fig. 1A, $P<0.001$). Then, the protein expression levels of BZW1 was detected by IHC. As shown in Fig. 1B-E, positive staining of BZW1 was mainly located in the cell cytoplasm as brown and yellow. Semiquantitative analysis shown that the high-expression rate of BZW1 in prostate cancer and non-cancerous prostate tissues were 68.4% and 32.4%, and the difference was statistically significant (Table 1, $P<0.001$).

| Types                           | N  | BZW1              | $P$ value |
|---------------------------------|----|-------------------|-----------|
|                                 |    | low-expression    | high-expression |   |
| PCa tissues                     | 136| 43 (31.6)         | 93 (68.4)  | <0.001 |
| Non-cancerous prostate tissues  | 136| 92 (67.6)         | 44 (32.4)  |         |

To investigate the clinical significance of BZW1 in prostate cancer, the correlation between BZW1 expression and clinicalpathological characters was investigated. Results shown BZW1 high-expression was significantly correlated with T stage, lymph node metastasis, PSA and Gleason score ($P<0.05$,
Table 2). However, no significant correlation was observed in BZW1 expression with age and smoke history ($P > 0.05$, Table 2). Furthermore, Kaplan-Meier analysis revealed that patients with BZW1 high-expression presented unfavorable prognosis than those with BZW1 low-expression (Fig. 2, $P = 0.002$). T stage, lymph node metastasis, PSA and Gleason score rather than age and smoke history were significantly correlated with overall survival time ($P < 0.05$, Table 3). Moreover, multivariate Cox regression analysis shown that BZW1 expression, T stage, lymph node metastasis, PSA and Gleason score were independent prognostic factors for overall survival in prostate cancer (Table 4, $P < 0.05$).

Table 2

| Clinical-pathological characters | N     | BZW1       | P value |
|---------------------------------|-------|------------|---------|
|                                 |       | low-expression | high-expression |       |
| Age (years)                     |       |             |         |
| ≤ 60                            | 60    | 24          | 36       | 0.067  |
| > 60                            | 76    | 19          | 57       |         |
| Smoke history                   |       |             |         |
| Negative                        | 79    | 29          | 40       | 0.058  |
| Positive                        | 57    | 14          | 43       |         |
| T stage                         |       |             |         |
| T1-T2                           | 65    | 34          | 31       | < 0.001 |
| T3                              | 71    | 9           | 62       |         |
| Lymph node metastasis           |       |             |         |
| Negative                        | 70    | 33          | 37       | < 0.001 |
| Positive                        | 66    | 10          | 56       |         |
| PSA (ng/ml)                     |       |             |         |
| < 10                            | 34    | 18          | 16       | 0.003  |
| ≥ 10                            | 102   | 25          | 77       |         |
| Gleason Score                   |       |             |         |
| < 8                             | 73    | 34          | 39       | < 0.001 |
| ≥ 8                             | 63    | 9           | 54       |         |
Table 3  
Survival analysis was performed by Kaplan-Meier method

| Variables                        | N  | Mean survival time (Month, 95% CI) | P value |
|----------------------------------|----|-----------------------------------|---------|
| BZW1 expression                  |    |                                   |         |
| Low-expression                   | 43 | 56 (51–61)                        | 0.002   |
| High-expression                  | 93 | 44 (40–48)                        |         |
| Age (years)                      |    |                                   |         |
| ≤ 60                             | 60 | 48 (43–53)                        | 0.969   |
| > 60                             | 76 | 47 (42–52)                        |         |
| Smoke history                    |    |                                   |         |
| Negative                         | 79 | 47 (42–52)                        | 0.439   |
| Positive                         | 57 | 49 (44–54)                        |         |
| T stage                          |    |                                   |         |
| T1-T2                            | 65 | 55 (51–59)                        | < 0.001 |
| T3                               | 71 | 41 (37–45)                        |         |
| Lymph node metastasis            |    |                                   |         |
| Negative                         | 70 | 54 (50–58)                        | < 0.001 |
| Positive                         | 66 | 41 (37–45)                        |         |
| PSA (ng/ml)                      |    |                                   |         |
| < 10                             | 34 | 55 (49–61)                        | 0.024   |
| ≥ 10                             | 102| 45 (41–49)                        |         |
| Gleason Score                    |    |                                   |         |
| < 8                              | 73 | 55 (51–59)                        | < 0.001 |
| ≥ 8                              | 63 | 38 (34–42)                        |         |
Table 4
Prognostic factors were analyzed by Cox’s proportional hazards model

| Variables                                      | Hazard rate | 95% CI    | P value |
|-----------------------------------------------|-------------|-----------|---------|
| BZW1 (High-expression VS Low-expression)      | 3.394       | 1.658–6.947 | 0.001   |
| Age (≤ 60 years VS > 60 years)                | 0.686       | 0.385–1.223 | 0.202   |
| Smoke history (Positive VS Negative)          | 0.582       | 0.327–1.039 | 0.067   |
| T stage (T3 VS T1-T2)                         | 2.878       | 1.614–5.132 | < 0.001 |
| PSA (≥ 10 ng/ml VS < 10 ng/ml )               | 2.096       | 1.056–4.163 | 0.034   |
| Lymph node metastasis (Positive VS Negative)  | 2.636       | 1.516–4.584 | 0.001   |
| Gleason Score (≥ 8 VS < 8)                    | 3.235       | 1.857–5.635 | < 0.001 |

**BZW1 promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway**

To explore the biological functions of BZW1 in prostate cancer, the influence of BZW1 expression on cell proliferation was investigated. As shown in Fig. 3A, BZW1 was highly expressed in PC3 cells, but was relatively lower in DU145 and LnCap cells. Thus, BZW1 expression was knocked down in PC3 cells and over-expressed in LnCap cells. QRT-PCR and Western blot analysis shown BZW1 down-regulation and up-regulation were successfully performed (Fig. 3B and 3C). Then, cell proliferation was evaluated by CCK-8 and Colony formation assays in vitro. CCK-8 assay showed that BZW1 knockdown significantly inhibited the proliferation in PC3 cells (Fig. 3D), while BZW1 over-expression significantly promoted the proliferation in LnCap cells. The colony number in cells with BZW1 down-regulation was significantly decreased, while was significantly increased in cells with BZW1 over-expression (Fig. 4A). To further investigate the effect of BZW1 expression on cell proliferation, xenografts in vivo was performed. Results showed that the size and weight of tumor with BZW1 knockdown were significantly decreased compared with those in NC groups (Fig. 4B and 4C).

To explore the potential mechanism of BZW1, TGF-β1/Smad pathway was investigated. As shown in Fig. 4D, the expression of TGF-β1 was significantly decreased with the knockdown of BZW1, while was significantly up-regulated by BZW1 over-expression. The protein expression levels of Smad1 and Smad3 were unchanged regardless of whether the BZW1 expression interference, while BZW1 down-regulation resulted in the decrease of p-Smad1 and p-Smad3.

**Discussion**

BZW1, as one of transcription factors, encode a N-terminal bZIP domain and a C-terminal nucleotide binding domain [11–12]. The proteins and transcription factors of bZIP domain play crucial roles in cancer development [17–18]. Recently, BZW1 over-expression was observed in mucoepidermoid
carcinoma [14] and lung adenocarcinoma [16]. However, the role of BZW1 in prostate cancer remains unknown.

Here, the expression and clinical significance of BZW1 was investigated in prostate cancer. Results shown that the mRNA and protein levels of BZW1 in prostate cancer were significantly higher compared with those in non-cancerous tissues. These data indicated that BZW1 overexpression was associated with the formation of prostate cancer, which was consistent with the observations in mucoepidermoid carcinoma [14] and lung adenocarcinoma [16]. BZW1 over-expression might be helpful for the diagnosis of prostate cancer. In addition, BZW1 over-expression significantly correlated with T stage, lymph node metastasis, PSA and Gleason score, suggesting that BZW1 over-expression was connected with the progression of PCa. Moreover, survival analysis shown that BZW1 as well as T stage, lymph node metastasis, PSA and Gleason score were associated with patients’ survival, which could be as independent prognostic factors in PCa. Moreover, Chiou et al [16] reported BZW1 over-expression was an independent poor prognosis marker in lung adenocarcinoma.

Subsequently, the influence of BZW1 expression on cell proliferation and its potential mechanism were explored. Results shown BZW1 down-regulation significantly suppressed cell proliferation, while BZW1 over-expression significantly promoted cell proliferation in vitro. Xenografts assays further validated that BZW1 knockdown significantly inhibited the proliferation of prostate cancer in vivo. To explore the potential mechanism of BZW1, TGF-β1/Smad pathway was investigated. It is well known that TGF-β/Smad pathway is involved in cell proliferation [19–21]. Results shown that BZW1 over-expression activated the TGF-β1/Smad pathway. Thus, these data indicated that BZW1 over-expression promoted cell proliferation, which was connected with the TGF-β1/Smad pathway.

Conclusion

These data indicate that BZW1 is highly expressed in prostate cancer and correlates with tumor progression and prognosis. Moreover, BZW1 overexpression promotes cell proliferation by regulating TGF-β1/Smad pathway.

Declarations

Not applicable.

Declarations

Authors’ contributions

KL conceived and designed the study. TCL and ZLS performed the analysis. JYW and CTX coordinated the statistical analyses of results. KL and TCL wrote the manuscript. All authors read and approved the manuscript. All authors consent for publication.
Funding

This study is supported by the Pearl River S&T Nova Program of Guangzhou (No. 201710010039), Basic Service Charge Young Teachers Cultivation Project of Sun Yat-sen University (17ykpy48) and National Natural Science Foundation (No. 81771573). The design of the study, collection of samples, analysis of results, interpretation of data, and writing of the manuscript was done by the authors (for details on authors’ contribution see below).

Availability of data and materials

The datasets used and analyzed during this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was reviewed and approved by the internal review boards (IRB) of the involved institutions: Sun Yat-sen University. (No. Z81771573).

All eligible subjects signed an informed consent to participate in this study.

Consent for publication

Not applicable.

Competing interests

All author declare they have no financial disclosures and conflicts of interest.

References

1. Li Z, Wei D, Zhu C, Zhang Q. Effect of a patient education and rehabilitation program on anxiety, depression and quality of life in muscle invasive Prostate cancer patients treated with adjuvant chemotherapy. Medicine (Baltimore). 2019, 98(44): e17437.

2. Zhao F, Yu X, Xu M, Ye S, Zang S, Zhong W, Ren G, Chen X, Yan S. Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study. Front Oncol. 2020, 9:1467.

3. Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol, 2018, 25(6): 524–531.

4. Sakamoto S. Editorial Comment to Epidemiology of prostate cancer in Asian countries. Int J Urol, 2018, 25(6): 531–532.
5. Saika T, Miura N, Fukumoto T, Yanagihara Y, Miyauchi Y, Kikugawa T. Role of robot-assisted radical prostatectomy in locally advanced prostate cancer. Int. J. Urol. 2018, 25: 30–35.

6. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012, 61: 1079–1092.

7. Zhu YP, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Zhu Y, Shi GH. Prevalence of incidental prostate cancer in patients undergoing radical cystoprostatectomy: data from China and other Asian countries. Asian J Androl 2009, 11(1): 104–108.

8. Liu X, Yu C, Bi Y, Zhang ZJ. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health. 2019, 172: 70–80.

9. Lin J, Yu X, Yang X, Jin J, Zhou L, Liu L, Su J, Li Y, Shang M. High Incidence of Incidental Prostate Cancer in Transurethral Resection of Prostate Specimens in China. The Value of Pathologic Review. Anal Quant Cytopathol Histopathol, 2016, 38(1): 31–37.

10. Kodama H, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Narita T, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer. Clin Genitourin Cancer. 2019, 17(6): e1091-e1098.

11. Machado RD, Pauciulo MW, Fretwell N, Veal C, Thomson JR, Vilarino Guell C, Aldred M, Brannon CA, Trembath RC, Nichols WC. A physical and transcript map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension. The International PPH Consortium. Genomics. 2000, 68(2): 220–228.

12. Nomura N, Nagase T, Miyajima N, Sazuka T, Tanaka A, Sato S, Seki N, Kawarabayasi Y, Ishikawa K, Tabata S. Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. 1994, 1(5): 223–229.

13. Mitra P, Vaughan PS, Stein JL, Stein GS, van Wijnen AJ. Purification and functional analysis of a novel leucine-zipper/nucleotide-fold protein, BZAP45, stimulating cell cycle regulated histone H4 gene transcription. Biochemistry. 2001, 40: 10693–10699.

14. Li S, Chai Z, Li Y, Liu D, Bai Z, Li Y, Li Y, Situ Z. BZW1, a novel proliferation regulator that promotes growth of salivary mucoepidermoid carcinoma. Cancer letters. 2009, 284: 86–94.

15. Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PloS one. 2013, 8: e82241.
16. Chiou J, Chang YC, Jan YH, Tsai HF, Yang CJ, Huang MS, Yu YL, Hsiao M. Overexpression of BZW1 is an independent poor prognosis marker and its down-regulation suppresses lung adenocarcinoma metastasis. Sci Rep. 2019, 9(1): 14624.

17. Newman JR, Keating AE. Comprehensive identification of human bZIP interactions with coiled-coil arrays. Science (New York, N.Y.) 2003, 300: 2097–2101.

18. Vinson C, Acharya A, Taparowsky EJ. Deciphering B-ZIP transcription factor interactions in vitro and in vivo. Biochimica et biophysica acta. 2006, 1759: 4–12.

19. Zhao Y, Wang L, Wang Y, Dong S, Yang S, Guan Y, Wu X. Astragaloside IV inhibits cell proliferation in vulvar squamous cell carcinoma through the TGF-β/Smad signaling pathway. Dermatol Ther. 2019, 32(4): e12802.

20. Bi JG, Zheng JF, Li Q, Bao SY, Yu XF, Xu P, Liao CX. MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-β/Smad pathway in hepatocellular carcinoma. Int J Biochem Cell Biol. 2019, 106: 107–116.

21. Romero D, Kawano Y, Bengoa N, Walker MM, Maltry N, Niehrs C, Waxman J, Kypta R. Downregulation of Dickkopf-3 disrupts prostate acinar morphogenesis through TGF-β/Smad signalling. J Cell Sci. 2013, 126(Pt 8): 1858–1867.

Figures
The expression levels of BZW1 were detected in prostate cancer. A: qRT-PCR revealed that the mRNA levels of BZW1 were higher in PCa compared with those in NC. (NC: non-cancerous prostate tissues). B: BZW1 low-expression in non-cancerous prostate tissues by IHC (Score=0). C: BZW1 low-expression in PCa by IHC (Score=2). D: BZW1 high-expression in PCa by IHC (Score=4). E: BZW1 high-expression in PCa by IHC (Score=6).
Kaplan-Meier survival analysis shown patients with BZW1 over-expression had unfavorable survival.
Figure 3

BZW1 overexpression promoted cell proliferation in vitro. A: The protein expression of BZW1 was detected in prostate cancer cell lines by Western blot. B: qRT-PCR analysis revealed that BZW1 down-regulation and up-regulation were successfully performed. C: Western blot analysis revealed that BZW1 down-regulation and up-regulation were successfully performed. D: CCK-8 assay shown BZW1 down-regulation significantly inhibited cell proliferation, while BZW1 overexpression significantly promoted cell proliferation. (Full-length blots/gels are presented in Supplementary Figure)
BZW1 overexpression promoted cell proliferation in vivo. A: BZW1 overexpression promoted colony formation. B: Xenografts assay indicated tumor size was decreased by down-regulating the expression of BZW1. C: Xenografts assay indicated tumor weight was significantly reduced by down-regulating the expression of BZW1. D: BZW1 over-expression activated the TGF-β/Smad pathway. (Full-length blots/gels are presented in Supplementary Figure)
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supplementarymaterial.doc